13 completed. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 2 | Completed 2 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) IFB-088 50mg/day, Placebo, Riluzole 100mg/day - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | InFlectis BioScience | 51 | 2022-12-02 | 2025-10-10 |
| A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS PrimeC, Placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | NeuroSense Therapeutics Ltd. | 69 | 2022-05-31 | 2025-09-05 |
| Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis LAM-002A, Placebo - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | IRulya Therapeutics Inc. | 15 | 2021-12-23 | 2026-09-29 |
| Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS Fixed dose combination Ciprofloxacin/Celecoxib - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | NeuroSense Therapeutics Ltd. | 16 | 2019-11-25 | 2021-03-03 |
| A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) Triheptanoin - ALS | Phase 1 / Phase 2 | Completed | Richard Bedlack, M.D., Ph.D. | 15 | 2018-06-21 | 2019-12-24 |
| Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis Ranolazine 500 MG, Ranolazine 1000 MG - ALS | Phase 2 | Completed | University of Kansas Medical Center | 14 | 2018-06-11 | 2024-12-09 |
| Open Label Extension Study of AMX0035 in Patients With ALS AMX0035 - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | Amylyx Pharmaceuticals Inc. | 90 | 2018-03-29 | 2025-08-13 |
| Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS) Perampanel, placebo - ALS | Phase 2 | Completed | Tokyo Medical University | 66 | 2017-04-24 | 2021-01-15 |
| Effect of MD1003 in Amyotrophic Lateral Sclerosis MD1003, Placebo oral capsule - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | MedDay Pharmaceuticals SA | 30 | 2016-06-29 | 2019-06-04 |
| A Trial of Tocilizumab in ALS Subjects Tocilizumab, Placebo - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Barrow Neurological Institute | 22 | 2015-11-01 | 2019-12-18 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Completed | Corestemchemon, Inc. | 72 | 2011-02-01 | 2022-03-17 |
| Talampanel for Amyotrophic Lateral Sclerosis (ALS) Talampanel, placebo - ALS | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 559 | 2008-09-01 | 2011-10-21 |
| Phase II Study Using Thalidomide for the Treatment of ALS Thalidomide - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | Dartmouth-Hitchcock Medical Center | 24 | 2005-02-01 | 2007-11-21 |
Amyotrophic Lateral Sclerosis (9) · Motor Neuron Disease (4) · Frontotemporal Dementia With Motor Neuron Disease (1) · Neurodegenerative Diseases (1)
Central Nervous System Diseases (9) · Metabolic Diseases (9) · Nervous System Diseases (9) · Neuromuscular Diseases (9) · Nutritional and Metabolic Diseases (9) · Proteostasis Deficiencies (9) · Spinal Cord Diseases (9) · TDP-43 Proteinopathies (9) · Neurodegenerative Diseases (8) · Motor Neuron Disease (5)
4-phenylbutyric acid (1) · Biotin (1) · Celecoxib (1) · Control Groups (1) · Ranolazine (1) · Riluzole (1) · Sodium Chloride (1) · Thalidomide (1) · perampanel (1) · sodium phenylbutyrate and taurursodiol (1) · talampanel (1) · tocilizumab (1) · triheptanoin (1) · ursodoxicoltaurine (1)
NeuroSense Therapeutics Ltd. (2) · Amylyx Pharmaceuticals Inc. (1) · Barrow Neurological Institute (1) · Corestemchemon, Inc. (1) · Dartmouth-Hitchcock Medical Center (1) · IRulya Therapeutics Inc. (1) · InFlectis BioScience (1) · MedDay Pharmaceuticals SA (1) · Richard Bedlack, M.D., Ph.D. (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · Tokyo Medical University (1) · University of Kansas Medical Center (1)
United States (7) · France (3) · Israel (3) · Italy (3) · Canada (2) · Belgium (1) · Germany (1) · Hungary (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1)
Elijah Stommel (1) · Giuseppe Lauria, Pr (1) · Jeffrey Statland, MD (1) · Richard S Bedlack, MD PhD (1) · Sabrina Paganoni, MD, PhD (1) · Seung Hyun Kim, M.D., Ph.D. (1) · Shafeeq Ladha, MD (1) · Shahram Attarian, Pr (1) · Suma Babu, M.D. (1) · Tomohiro Haga (1) · Vivian Drory, MD (1)
PMID 25934946, PMID 30048006, PMID 32140672, PMID 33063909, PMID 34075589, PMID 35508892, PMID 35577511, PMID 38606777, PMID 41837970